Prescient Therapeutics Limited (PSTTF) Research

Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations. Furthermore, Prescient maintains a strategic partnership with The University of Texas MD Anderson Cancer Center, focused on the development of a novel blood cancer binder for their OmniCAR platform. Established in 1986, the company adopted its current name, Prescient Therapeutics Limited, in December 2014, having previously operated as Virax Holdings Limited.

Open Prescient Therapeutics Limited (PSTTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.